In this week’s issue of The Savvy Diabetic:
-
- PharmaSens/SiBionics All-in-One Insulin Patch Pump
- EU Limits Chinese Access to Medtech Contracts
- Next-Gen Medtronic Insulin Pumps
- New Study: Semaglutide in Adults T1Ds
- $10.6 Billion Medicare Fraud Scheme by 11 Eastern Europeans
- Beta Bionics 2025 ADA Investor Presentation
PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump by Sean Whooley for DrugDeliveryBusiness.com, 23 June 2025.
Current automated insulin delivery platforms — like those offered by Insulet, Tandem Diabetes Care, Medtronic, Beta Bionics, and Sequel Med Tech — link separate devices. The pump itself is either tubeless and placed on the body, or worn on clothing with tubing delivering insulin to the body. They communicate with a CGM worn elsewhere on the body, typically the arm or the torso.
In the case of PharmaSens and SiBionics, all-in-one really means all-in-one. By combining a pump and a CGM into one device, the companies aim to provide a differentiated offering to the diabetes community.
The two companies announced plans to develop the next-generation Niia Signature insulin patch pump. The all-in-one wearable device would integrate insulin delivery from Switzerland-based PharmaSens and glucose sensing from China-based SiBionics into a single, compact automated patch pump system. At the American Diabetes Association’s 85th Scientific Sessions in Chicago, PharmaSens CEO Marcel Both and SiBionics Chief Strategy Officer Patrick Nowlin explained the aim of the two companies in providing this new technology to the diabetes community. “We worked fast. That’s what this collaboration needs to be,” said Both. “Because we want to be the first. We are going to be the first with an all-in-one device on the market.”
Read more: PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
EU limits Chinese companies’ access to public medtech contracts by Susan Kelly for MedTechDive.com, 23 June 2025.
The European Commission announced that it will exclude Chinese suppliers from participating in government purchases of medical devices exceeding 5 million euros ($5.8 million). Additionally, no successful bids can have more than 50% of their inputs sourced from China.
The decision to limit Chinese companies in the European Union’s public procurement market is a response to China’s longtime exclusion of EU-made medical devices from Chinese government contracts, the commission said. The action, which follows a vote by EU member states to support restrictions, is intended to incentivize China to end discrimination against EU companies, according to a statement. “Our aim with these measures is to level the playing field for EU businesses,” Maroš Šefčovič, commissioner for trade and economic security, interinstitutional relations and transparency, said in the statement. “We remain committed to dialogue with China to resolve these issues. Our aim with these measures is to level the playing field for EU businesses,”
Read more: EU limits Chinese companies’ access to public medtech contracts
Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way by Sean Whooley for DrugDeliveryBusiness.com, 23 June 2025.
Medtronic Minimed expects to submit a new automated insulin delivery system, the MiniMed Flex (8 series) pump, to the FDA by the end of the fiscal year. (Medtronic’s fiscal year ends in April, meaning the submission could come by spring 2026.) It also continues to prepare for a label expansion to type 2 diabetes for the currently available MiniMed 780G. Finally, analysts say they received a look at the company’s in-development MiniMed Fit patch pump.
The MiniMed Fit also features a 300-unit insulin capacity and a seven-day wear time. Developed internally at Medtronic, it has both a rechargeable battery and a disposable component. The analysts say the battery should last longer than seven days per charge, and users receive two batteries as a standard. Separately, MiniMed is developing a new algorithm beyond the SmartGuard Advance algorithm.
MiniMed Fit could rival leader Insulet and potential competitors Beta Bionics and Tandem Diabetes Care, who are developing their own. PharmaSens and SiBionics also recently unveiled their entry, an all-in-one device.
Read more: Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way
Newest study on the benefit of using semaglutide in the T1D Population: Semaglutide in Adults with Type 1 Diabetes and Obesity by Viral N. Shah, MD et al, published by NEJM.org, 23 June 2025
Background: Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes are not established.
Conclusions: In adults with type 1 diabetes and obesity, semaglutide treatment, compared with AID use alone, significantly improved achievement of a composite of time in range of greater than 70%, with time below range of less than 4%, and a 5% body weight reduction.
Read more: Semaglutide in Adults with Type 1 Diabetes and Obesity
11 Eastern Europeans charged in $10.6 billion Medicare fraud scheme by Jeremy Roebuck & Dan Diamond for WashingtonPost.com, 26 June 2025.
Federal prosecutors unveiled charges against 11 Eastern Europeans, accusing them of running a sophisticated, $10.6 billion Medicare fraud scheme in what appears to be one of the largest such busts in government history. According to an indictment unsealed in federal court in New York, the group based in Russia and elsewhere submitted billions of dollars in false health care claims using personal information stolen from more than 1 million Americans in all 50 states. Prosecutors say the organization bought more than 30 previously legitimate U.S. companies and turned them from lawful businesses into consistent vehicles for fraud.
The scheme relied on submitting fraudulent claims to Medicare to pay for durable medical equipment, or DME, a frequent target for criminal organizations seeking to raid the roughly $1 trillion federal insurance program and exploit older Americans’ personal information. Although Medicare was able to flag many improper benefit claims before they were paid out, the indictment states, the group still managed to collect nearly $1 billion in illegal proceeds over a three-year period.
Read more: 11 Eastern Europeans charged in $10.6 billion Medicare fraud scheme
Beta Bionics Presentation, 2025 ADA Investor & Analyst Event, Chicago, June 2025.
